Hard and Soft Tissue Maintenance Around Implants With a Sloped Configuration

Digital scans will be done at first, 5th, 6th, 8th, and 10th visit to get the possibility to determine and compare volume changing and stability at augmented or not augmented implant sites during follow up visits.

According to standard procedure, patients will receive an antibiotic regime (Augmentin 1g, 2x1, GlaxoSmithKline, Vienna, Austria; in case of penicillin-allergy: DalacinC 300mg, 3x1, Pfizer, Vienna, Austria) starting one day prior surgery till 3 days after surgery. Before implant surgery patients are advised to rinse with a local antiseptic chlorhexidine gluconate solution (Chlorhexamed forte 2mg/ml, GlaxoSmithKline, Vienna, Austria). Articain is used for local anesthesia (Ultracain D-S forte with epinephrine 1:100.000, Sanofi Aventis, Vienna, Austria). These drugs are not object of the investigation. After flap elevation the lingual-buccal height discrepancy and bone width is measured using a periodontal probe. The implant surgery is done following the standard surgical protocol of implant placement of the Department of Dental medicine and Oral Health Graz using a pilot drill guide. After implant insertion the marginal bone level will be measured using a periodontal probe. Implant shoulder attends as a reference.

After implant insertion (Astra Tech Implant EV C or Astra Tech Implant Profile EV C, Dentsply Implants Manufacturing GmbH, Hanau, Germany), GBR (Astra Tech Implant EV C) and a healing period of approximately 3 months for both groups, the implants will be uncovered following the standard protocol of the Department of Dental medicine and Oral Health Graz, and titanium gingiva formers will be placed (non-investigational devices). After implant recovery the marginal bone level will be measured again using a periodontal probe. Implant shoulder attends as a reference.

All patients will receive CE-certified gingiva formers, which are used in the Department of Dental Medicine and Oral Health Graz and which are approved in Austria. 1 week after reentry the sutures will be removed and the digital impression (PrimeScan) for the CAD/CAM (Computer Aided Design /Computer Aided Manufacturing) manufactured single implant crowns using customized individual abutments (Atlantis, Mölndal, Sweden) will be done.

Radiographic examinations (single-tooth x-ray) will be done at implant recovery (3 months after implant placement, visit 6), visit 10 and visit 11.

A complete periodontal status (PD=probing depth, BOP= Bleeding on probing, PI= Plaque index) should be evaluated at the first visit (before implant placement). These parameters (PD, BOP, PI) as well as Papilla Index should be performed 8, 12, and 15 months after implant placement at implant and reference tooth site. In addition, PD and Papilla Index will be performed 4 months after implant placement (at time of integration of the implant crown). At the first visit, complete periodontal status will be evaluated to prove if the participant fulfills the inclusion criteria. During the following visits only reference teeth (neighboring tooth or teeth to the implant) and the implant site will be determined.

The soft tissue maintenance will be detected using the Papilla Index by Jemt (Jemt T, 1997) which assesses the size of interproximal gingival papillae adjacent to single implant restorations. Using this, one can determine the papilla remodeling between a dental implant and each neighboring tooth.

Intraoral photographs will be taken at every study visit (except suture removal), evaluating the esthetic outcome.

Oral Health Impact Profile (OHIP-G 14) will be done at the first visit and 12 months after implant placement. The Oral Health Impact Profile as a self-rating patient-centered instrument designed to assess the oral health-related quality of life within the last month. Especially, the following dimensions are captured by the OHIP-G 14: functional Limitation (e.g., "pronouncing any words because of problems with your teeth, mouth, dentures, or jaw?") and physical Pain (e.g., "Have you had painful aching in your mouth"). 14 questions are raised, which are answered using a rating scale from 0 (never) to 4 (very often).

A questionnaire evaluating patient satisfaction will be performed one week after implant surgery and 12 months after implant placement.

Visual analog scale (VAS) for subjective measurement of pain will be performed immediately and 1 week after implant placement using a combined VAS and numeric rating scale (NRS) The scale ranges from 0 (smiling face), which means no pain, to 10 (sad face), which means most pain imaginable).

GCP Statement: This study will be conducted in compliance with the principles of the Declaration of Helsinki, the ICH-GCP guidelines and in accordance with the relevant provisions of Austrian Medical Devices Act (MPG), the European Directive on implantable medical devices (90/385/EEC), the Styrian Hospitals Act (KALG), the Federal Law on hospitals (KAKuG), the EN-ISO standards 14155-1 and -2, EN ISO 14971, 10993 and all other ENISO eligible relevant legislations.

Inclusion criteria

• Written consent after clarification
• capability of giving an informed consent
• good health as defined by the subjects medical history (no contraindications as described in the exclusion criteria below)
• age 18 years of age and over
• Good periodontal status: BOP < 20%, PI < 30%, no PD > 4mm
• No heavy smokers (< 10 cigarettes/day)
• At least 1 missing tooth in the premolar and molar region (in selected cases in the frontal area) either in the maxilla or in the mandible requiring implant therapy for reconstruction.
• implant site must present a buccal bone defect not extending a lingual-buccal or buccal-palatinal height discrepancy of 5mm and a sufficient bone width for simultaneously GBR procedure
• implant site must present at least a neighbouring tooth on its mesial aspect

Exclusion criteria

• Insufficient bone volume for implant placement requiring a sinus floor elevation or extensive bone augmentation
• Heavy Smokers (>10 cigarettes/day)
• Medication with a contraindication for implant therapy
• Skeletal immaturity
• Any active malignancy or ongoing treatment for malignancy
• An active infection at the operative site
• Contraindications to the class of drugs which are used at regular surgical procedures, e.g. known hypersensitivity or allergy to class of drugs or the investigational product, except penicillin-allergy
• Pregnancy
• unable or unwilling to return for follow-up visits for a period of at least 16 months